Pfizer

YTD

ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

CEO

Albert Bourla

CEOAlbert Bourla

Employees

81,000

Employees81,000

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

1849

Founded1849

Employees

81,000

Employees81,000

PFE Key Statistics

Market cap

145.74B

Market cap145.74B

Price-Earnings ratio

18.25

Price-Earnings ratio18.25

Dividend yield

6.57%

Dividend yield6.57%

Average volume

44.60M

Average volume44.60M

High today

$25.76

High today$25.76

Low today

$25.50

Low today$25.50

Open price

$25.65

Open price$25.65

Volume

30.30M

Volume30.30M

52 Week high

$31.54

52 Week high$31.54

52 Week low

$24.48

52 Week low$24.48

PFE News

Simply Wall St 2d

Pfizer Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits

is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company adv...

Benzinga 3d

Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators

In August 2024, Pfizer Inc PFE introduced the PfizerForAll digital platform in collaboration with UpScriptHealth, Alto Pharmacy, and Instacart. In a letter add...

TipRanks 3d

Arvinas price target lowered to $12 from $48 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the company and partner Pf...

Analyst ratings

54%

of 24 ratings

Buy

41.7%

Hold

54.2%

Sell

4.2%

More PFE News

Seeking Alpha 4d

Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestra...

Quartz 5d

Lawmakers demand answers from RFK Jr. over Trump dinners with pharma execs

Three U.S. senators are urging Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to disclose details about several private dinners he attended wit...

Benzinga 5d

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adul...

TipRanks 5d

Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in a...